Zolmitriptan Tablets

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition

Issued and maintained by the United States Pharmacopeial Convention (USP)

DOWNLOAD PDF HERE

1 DEFINITION

Zolmitriptan Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂).

2 IDENTIFICATION

A. The UV spectrum of the zolmitriptan peak in the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

3 ASSAY

3.1 PROCEDURE

Buffer: Dissolve 2 mL of triethylamine in 1 L of water. Adjust with phosphoric acid to a pH of 3.0.

Mobile phase: Acetonitrile and Buffer (15:85)

Standard stock solution: 0.25 mg/mL of USP Zolmitriptan RS in methanol. Sonicate if necessary to aid dissolution.

Standard solution: 0.025 mg/mL of USP Zolmitriptan RS in Mobile phase from Standard stock solution

Sample stock solution: Nominally 0.25 mg/mL of zolmitriptan from Tablets in methanol prepared as follows. Transfer NLT 5 Tablets to a suitable volumetric flask. Add 70% of the flask volume of methanol. Sonicate for 30 min. Cool to room temperature, and dilute with methanol to volume.

Sample solution: Nominally 0.025 mg/mL of zolmitriptan in Mobile phase from Sample stock solution passed through a suitable membrane filter of 0.45-µm pore size

3.2 Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 225 nm . For Identification A, a diode array can be used in the wavelength range of 200-300 nm.

Column: 4.6-mm x 15-cm; 5-µm packing L1

Column temperature: 30°

Flow rate: 1 mL/min

Injection volume: 20 µL

Relative standard deviation: NMT 2.0%

Run time: NLT 2.5 times the retention time of zolmitriptan

3.3 System suitability

Sample: Standard solution

Suitability requirements

Tailing factor: NMT 2.0

3.4 Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) in the portion of Tablets taken:

Result = (r_U/r_S) x (C_S/C_U) x 100

r_U = peak response of zolmitriptan from the Sample solution

r_S = peak response of zolmitriptan from the Standard solution

C_S = concentration of USP Zolmitriptan RS in the Standard solution (mg/mL)

C_U = nominal concentration of zolmitriptan in the Sample solution (mg/mL)

Acceptance criteria: 90.0%-110.0%

4 PERFORMANCE TESTS

4.1 DISSOLUTION (711)

4.1.1 Test 1

Medium: 0.1 N hydrochloric acid; 500 mL

Apparatus 2: 50 rpm

Time: 15 min

[NOTE-Analyze the sample under test using either the Chromatographic procedure or the Instrumental procedure.]

Chromatographic procedure

Buffer, Mobile phase, Standard stock solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.

Standard solution: (L/500) mg/mL of USP Zolmitriptan RS in Medium from Standard stock solution, where L is the Tablet label claim in mg

Sample solution: Pass a portion of the solution under test through a suitable membrane filter of 0.45-µm pore size.

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) dissolved:

Result = (r_U/r_S) x C_S x V x (1/L) x 100

r_U = peak response of zolmitriptan from the Sample solution

r_S = peak response of zolmitriptan from the Standard solution

C_S = concentration of USP Zolmitriptan RS in the Standard solution (mg/mL)

V = volume of Medium, 500 mL

L = label claim of zolmitriptan (mg/Tablet)

Instrumental procedure

Standard solution: 0.01 mg/mL of USP Zolmitriptan RS from Standard stock solution in Medium

Sample solution: Pass a portion of the solution under test through a suitable membrane filter of 0.2-µm pore size.

Instrumental conditions

Mode: UV

Analytical wavelength: About 283 nm

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) dissolved:

Result = (A_U/A_S) x C_S x V x (1/L) x 100

A_U = absorbance of the Sample solution

A_S = absorbance of the Standard solution

Cs = concentration of USP Zolmitriptan RS in the Standard solution (mg/mL)

V = volume of Medium, 500 mL

L = label claim of zolmitriptan (mg/Tablet)

Tolerances: NLT 80% (Q) of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) is dissolved.

4.1.2 Test 2: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.

Medium: 0.1 N hydrochloric acid; 500 mL

Apparatus 2: 50 rpm

Time: 30 min

Buffer: 5.8 g/L of ammonium dihydrogen phosphate in water. Adjust with triethylamine to a pH of 7.0.

Mobile phase: Acetonitrile and Buffer (15:85)

Standard solution: (L/500) mg/mL of USP Zolmitriptan RS in Medium, where L is the label claim in mg/Tablet

Sample solution: Pass a suitable portion of the solution under test through a suitable filter. Discard the first few mL of filtrate.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm x 15-cm; 5-µm packing 11

Column temperature: 40°

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: NLT 1.8 times the retention time of zolmitriptan

System suitability

Sample: Standard solution

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) dissolved:

Result = (r_U/r_S) x C_S x V x (1/L) × 100

r_U = peak response from the Sample solution

r_S = peak response from the Standard solution

C_S = concentration of USP Zolmitriptan RS in the Standard solution (mg/mL)

V = volume of Medium, 500 mL

L = label claim of zolmitriptan (mg/Tablet)

Tolerances: NLT 80% (Q) of the labeled amount of zolmitriptan (C₁₆H₂₁N₃O₂) is dissolved.

4.2 UNIFORMITY OF DOSAGE UNITS (905)

Meet the requirements

5 IMPURITIES

Change to read:

ORGANIC IMPURITIES

Solution A: 2.7 g/L of monobasic potassium phosphate in water

Solution B: Acetonitrile

Mobile phase: See Table 1.

Table 1

Diluent: Methanol and water (25:75)

System suitability stock solution: 0.2 mg/mL each of USP Zolmitriptan Related Compound E RS and USP Zolmitriptan Related Compound G RS in methanol

System suitability solution: 0.25 mg/mL of USP Zolmitriptan RS and 0.002 mg/mL each of USP Zolmitriptan Related Compound E RS and USP Zolmitriptan Related Compound G RS from System suitability stock solution in Diluent prepared as follows. Dissolve a suitable quantity of USP Zolmitriptan RS in a suitable volumetric flask containing 50% of the flask volume of Diluent. Sonicate to dissolve. Transfer a suitable volume of System suitability stock solution to the flask. Dilute with Diluent to volume.

Standard stock solution: 0.25 mg/mL of USP Zolmitriptan RS in methanol. Sonicate if necessary to aid dissolution.

Standard solution: 0.001 mg/mL of USP Zolmitriptan RS in Diluent from a suitable volume of Standard stock solution

Sample solution: Nominally 0.25 mg/mL of zolmitriptan from NLT 5 Tablets prepared as follows. Transfer the required number of Tablets to a suitable volumetric flask. Add 25% of the flask volume of methanol. Sonicate for 30 min with intermittent shaking. Cool to room temperature. Dilute with water to volume. Pass through a suitable filter of 0.45-µm pore size.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector

For zolmitriptan and zolmitriptan related compound E and any other unspecified degradation product: UV 223 nm

For zolmitriptan and zolmitriptan related compound G: UV 235 nm

Column: 4.6-mm x 15-cm; 5-µm packing L1

Column temperature: 30°

Flow rate: 1.5 mL/min

Injection volume: 20 µL

System suitability

Samples: System suitability solution and Standard solution

[NOTE-See Table 2 for relative retention times.]

Suitability requirements

Use 223 nm for System suitability evaluation.

Resolution: NLT 5.0 between zolmitriptan and zolmitriptan related compound E, System suitability solution

Tailing factor: NMT 2.0 for the zolmitriptan peak, Standard solution

Relative standard deviation: NMT 5.0%, Standard solution

Analysis

Samples: Standard solution and Sample solution (ERR 1-Nov-2018)

Calculate the percentage of zolmitriptan related compound G in the portion of the Tablets taken:

Result = (r_U/r_S) x (C_S/C_U) x (1/F) x 100

r_U = peak response of zolmitriptan related compound G at 235 nm from the Sample solution

r_S = peak response of zolmitriptan at 235 nm from the Standard solution

C_S = concentration of the USP Zolmitriptan RS in the Standard solution (mg/mL)

C_U = nominal concentration of zolmitriptan in the Sample solution (mg/mL)

F = relative response factor for zolmitriptan related compound G (see Table 2)

Calculate the percentage of zolmitriptan related compound E and any other unspecified degradation product in the portion of Tablets taken:

Result = (r_U/r_S) x (C_S/C_U) x (1/F) x 100

r_U = peak response of zolmitriptan related compound E or any other unspecified degradation product at 223 nm from the Sample solution

r_S = peak response of zolmitriptan at 223 nm from the Standard solution

C_S = concentration of the USP Zolmitriptan RS in the Standard solution (mg/mL)

C_U = nominal concentration of zolmitriptan in the Sample solution (mg/mL)

F = relative response factor (see Table 2)

Acceptance criteria: See Table 2. Disregard any impurity less than 0.05%.

Table 2

6 ADDITIONAL REQUIREMENTS

6.1 PACKAGING AND STORAGE

Preserve in well-closed, light-resistant containers. Store at controlled room temperature.

6.2 LABELING

When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.

6.3 USP REFERENCE STANDARDS (11)

USP Zolmitriptan RS

USP Zolmitriptan Related Compound E RS

(S)-N,N-Dimethyl-2-{5-[(2-oxooxazolidin-4-yl)methyl]-1H-indol-3-yl}ethanamine oxide.

C₁₆H₂₁N₃O₃ 303.36

USP Zolmitriptan Related Compound G RS

(S)-4-(4-Aminobenzyl)oxazolidin-2-one.

C₁₀H₁₂N₂O₂ 192.21